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Abstract: Evidence-based practice is an important component of health care service delivery. 
However, there is a tendency, embodied in tools such as Grades of Recommendation, Assess-
ment, Development, and Evaluation, to focus principally on the classification of study design, 
at the expense of a detailed assessment of the strengths and limitations of the individual study. 
Randomized controlled trials (RCTs), and in particular the classical “explanatory” RCT, have 
a privileged place in the hierarchy of evidence. However, classical RCTs have substantial 
limitations, most notably a lack of generalizability, which limit their direct applicability to 
clinical practice implementation. Pragmatic and observational studies can provide an invaluable 
perspective into real-world applicability. This evidence could be used more widely to comple-
ment ideal-condition results from classical RCTs, following the principle of triangulation. In 
this review article, we discuss several types of pragmatic and observational studies that could 
be used in this capacity. We discuss their particular strengths and how their limitations may be 
overcome and provide real-life examples by means of illustration.
Keywords: research methods, randomized controlled trials, pragmatic trials, observational 
studies, disease registries, evidence-based medicine
Introduction
Evidence-based practice is an important component in health care service delivery,1 
although its development into a formal paradigm is a relatively recent phenomenon. 
One characteristic feature of common conceptualizations of evidence-based medicine 
(EBM) is a focus on quality of evidence.2 It is of course important to consider the quality 
of evidence, since clinical practice recommendations based on low-quality evidence 
may not lead to high-quality clinical outcomes. However, one potential danger of this 
approach has been the emergence of an established hierarchy of evidence, which is 
based principally on the classification of study design selected, rather than the meth-
odological quality of the individual study. Randomized controlled trials (RCTs) hold 
a privileged place in this hierarchy. For example, the Grades of Recommendation, 
Assessment, Development, and Evaluation (GRADE) system,3 which is one common 
framework for EBM clinical guideline development, classifies randomized studies 
as “high” evidence and nonrandomized studies as “low” evidence. Therefore, in this 
approach, a well-designed robust nonrandomized study would be considered poorer 
evidence than a poorly designed randomized study with critical methodological flaws 
that make its conclusions highly unlikely to be valid. As peer review has its limitations,4 
it is important not to discount the possibility of the existence of poor-quality RCTs in 
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the published scientific literature. As such, it is concerning 
that systems such as GRADE place so much emphasis on 
study design classification, such as randomized trial or non-
randomized trial, at the expense of a more holistic evaluation 
of the methodological rigor of the individual study.
There are a variety of trial designs that can be classi-
fied as RCTs. Nevertheless, the classical (sometimes called 
“explanatory”) RCT remains at the pinnacle of the hierarchy 
of evidence, apart from systematic reviews and meta-analyses 
of RCTs. Nevertheless, the privileged place of the classical 
RCT, even if well designed, has come into question, especially 
in recent years. Such studies may be just too far removed 
from the realities of clinical practice to be able to reliably 
inform it.5 Classical RCTs seek to achieve optimal internal 
validity, but this comes at the cost of markedly reduced 
external validity (or generalizability). Sociodemographic 
biases frequently occur,6 often as a combination of barriers 
to recruitment of certain types of patients and very stringent 
inclusion criteria. For example, the classical RCT routinely 
excludes potential participants with multiple comorbidities, 
and this may exclude at least 89% of patients encountered 
in routine care.7 Older people are also markedly underrep-
resented in trials of pharmaceutical therapies they are likely 
to receive.8 Moreover, a study of recruitment to asthma and 
chronic obstructive pulmonary disease  trials showed that 
only 1% and 7% of the routine common patient populations, 
respectively, met common clinical trial inclusion criteria.9 
The most frequent criticism of clinical guidelines, systematic 
reviews, and RCTs by clinicians is a lack of consideration 
of the generalizability of the findings to routine clinical 
practice situations.10,11 Indeed, a Cochrane review of a series 
of relatively small RCTs recommended nebulized saline 
for bronchiolitis in infants,12 a recommendation that is not 
supported by any subsequent larger trials, such as that by 
Everard et al.13 EBM, however conceptualized, is not perfect 
and relies on the strengths and limitations of the extant body 
of evidence.
Although classical RCTs retain a privileged place in the 
hierarchy of evidence, their limitations, as discussed earlier, 
have been increasingly recognized by the academic commu-
nity. Bothwell et al claim that we are now “at a crucial point 
in the history of RCTs.”14 Traditionally, regulatory bodies 
required a strong body of evidence based on classical RCTs. 
Similarly, classical RCTs were prioritized in clinical guide-
lines. However, we are in a time when there may be a shift 
toward an increasing acceptance of the value of pragmatic 
RCTs and other nonclassical designs. Indeed, in the context of 
asthma research, the Brussels Declaration urges an increased 
focus on pragmatic and observational studies.15 It is important 
to note that there is evidence that well-designed observational 
studies do not systematically overestimate treatment effects 
compared to RCTs.16 Methodological triangulation is an 
important concept in social science research, and especially 
in qualitative research.17 This concept says that we can gain 
a greater understanding of a research question by studying 
it from different perspectives using different methodologies. 
Hitherto, this concept has not been popular in the field of 
the assessment of medical and other health care or public 
health interventions. Nevertheless, recognizing the different 
strengths and limitations of each method, it could be argued 
that a combination of evidence from classical RCTs with a 
focus on internal validity and more pragmatic designs with a 
focus on external validity and applicability to routine clinical 
practice could provide the strongest overall assessment of the 
available body of evidence.
The aim of this review is to provide a concise but informa-
tive overview of the ways in which pragmatic and observa-
tional studies can be valuable and informative for clinical and 
public health practice, while also offering some illustrative 
examples from different specialty areas.
Pragmatic trials of clinical interventions
Pragmatic trials of clinical interventions have a relatively 
longstanding history. Indeed, the distinction between classical 
RCTs and a more pragmatic RCT design was discussed back in 
the 1960s.18 The concept of the pragmatic RCT arose out of a 
recognition of some of the issues with classical RCTs that we 
have discussed earlier, most notably a lack of generalizability 
and applicability to routine classical practice. Therefore, these 
methodological concerns about classical RCTs are longstand-
ing rather than a recent occurrence. Nevertheless, pragmatic 
trials long remained as a minority approach on the edge of 
the RCT scene and undervalued by regulators. Starting in the 
1990s, there has been an increased interest in pragmatic trials 
within the academic medical community, leading to the pub-
lication of a number of commentaries. For example, Roland 
and Torgerson published an article in the BMJ outlining the 
key features and utility of pragmatic RCTs.19 Nevertheless, it 
was not until 2009 when the first formal tool to characterize 
the extent to which a given trial was pragmatic or explanatory 
was published: the Pragmatic-Explanatory Continuum Indica-
tor Summary (PRECIS) tool.20
In summary, according to PRECIS, pragmatic trials tend 
not to exclude based on comorbidities or compliance, they 
offer practitioners flexibility in how to apply the interven-
tion, use a wide range of clinical practitioners for both the 
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 intervention and the control group, use standard care as the 
comparator intervention, rely on administrative databases 
rather than formal follow-up visits, use a clinically mean-
ingful outcome measure, do not seek to measure or improve 
participant or practitioner compliance to the protocol, and 
use intention-to-treat analysis to assess how the treatment 
works under usual clinical conditions. An updated version 
called PRECIS-221 removed four of the original 10 domains 
and added three new domains: recruitment, setting, and orga-
nization. PRECIS-2 is also a well-validated tool and benefits 
from the increased granularity of responses offered by a 
Likert scale rather than binary answers for each component 
domain. Investigators considering designing a pragmatic 
trial could use PRECIS-2 to consider which combination of 
design features is likely to provide the most appropriate fit 
for a given situation.
A trade-off as we move along the continuum from 
explanatory to pragmatic comes in terms of increased gen-
eralizability at the cost of reduced internal validity. As a 
challenger to the classical RCT paradigm, it is unsurprising 
that pragmatic trials have faced criticism in some quarters, as 
reviewed, for example, by Patsopoulos.22 Potentially related 
to the traditional focus by regulators on explanatory RCTs, 
funding was reported in 2003 to be a barrier to the wider 
adaptation of pragmatic RCTs, because they were seen as 
poorly aligned to the priorities of major funding bodies.23 
However, in light of increasing recognition of the value of 
pragmatic RCTs for informing clinical practice, this situation 
may have changed or at least would be expected to do so soon. 
No more recent reports of such issues could be identified. 
Increased funding for pragmatic trials may be expected to 
follow an increased focus by governments on the impact of 
taxpayer-funded research.
While pragmatic RCTs have acknowledged limitations 
in terms of internal validity, they offer key advantages over 
explanatory trials that entitle them to form an important part 
of a trialist’s armamentarium. There are logistical challenges 
associated with conducting a pragmatic RCT, including issues 
of ethical barriers to genuinely unselected patient access, 
recruitment of investigators, and conducting the trial so as 
to mirror how the intervention would be delivered in routine 
clinical practice if it were to be adopted in routine practice. 
These challenges and potential solutions are reviewed in 
detail by Ford and Norrie.24 Nevertheless, if these challenges 
are successfully overcome and a pragmatic RCT is selected 
in an appropriate context, it offers unique advantages. For 
example, if the participants recruited to the trial correspond 
well to patients that would be encountered in routine practice, 
if those such as patients with multiple comorbidities who 
may be more likely to be nonresponsive to treatment are 
included in the study, if those who do not meet recognized 
diagnostic criteria but are being treated clinically as if they 
had the target condition are included, if the level of clinical 
attention to patients in the trial more closely represents that 
which would be offered in routine practice, if the intervention 
is delivered as it would be delivered in usual care allowing 
for differences in practice between individual clinicians 
that explanatory RCTs seek to eliminate – and nevertheless, 
a statistically and clinically significant intervention effect 
is found, then we can be confident that the intervention is 
likely to be effective should it be adopted in routine clinical 
practice. Conversely, if an intervention shows a robust effect 
in explanatory RCTs in ideal conditions but no clinically sig-
nificant effect is found in pragmatic RCTs, then it is unlikely 
to be effective if adopted in routine practice. Therefore, by 
telling us whether or not an intervention is likely to be effec-
tive in routine clinical practice, pragmatic RCTs are of high 
social value.25 For example, a landmark series of pragmatic 
RCTs funded by the US National Institute of Mental Health26 
provided invaluable evidence that currently available psycho-
tropic medications, licensed on the basis of the results from 
classical explanatory RCTs, are ineffective in a substantial 
proportion of real-life clinical practice patients within their 
licensed clinical indication.
Nonrandomized and observational 
studies of clinical interventions
Traditionally, observational research has been seen as a way 
of determining risk factors and mechanisms of actions that 
could serve as potential targets for therapeutic intervention, 
to be assessed in future RCTs. Nonrandomized studies have 
been seen as simply too prone to methodological issues such 
as confounding to be useful in the assessment of potential 
health care interventions, barring an overriding ethical or 
practical reason why randomized studies could not be con-
ducted. Clearly, observational research is useful for identi-
fying potential intervention targets. However, the results of 
observational research can be used to inform our clinical 
understanding of the nature of particular clinical conditions, 
which can in turn inform clinical decisions regarding which 
of a range of approved and available treatments to offer a 
particular patient, as well as guiding decisions regarding 
which treatments to fund. For example, the Aberdeen Schools 
Asthma Survey (ASAS), one of the longest-running asthma 
epidemiology studies worldwide, which is not explicitly a 
study of treatment options, has provided information that 
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eczema and asthma, despite frequent co-occurrence, are 
likely to have separable mechanisms of action27 and that 
clinicians should be aware that these are distinct conditions 
and use this to inform their diagnostic and treatment choices. 
Moreover, ASAS has demonstrated how asthma risk factors 
are not static, but instead involve over time and are responsive 
to social and environmental changes,28 and that, therefore, 
if clinicians encourage modification of risk factors such as 
protecting children from second-hand smoke, asthma risk 
may be reduced. Moreover, a review by Turner29 shows how 
observational evidence about childhood asthma and asthma 
exacerbations can inform the potential of greater personaliza-
tion of care in the future. Stratified medicine30 is an important 
concept, and one that should expand in terms of adaptation in 
routine practice in future. An important principle of stratified 
medicine is the realization that not all patients are the same. 
In contrast, RCTs, especially classical RCTs, assume that 
all patients are the same, and this is not a valid assumption.
Moreover, there has been renewed interest in how obser-
vational studies of health care interventions themselves can 
complement evidence from RCTs. However, such methods 
need to be used with care because such studies are more prone 
to limited internal validity than pragmatic RCTs. Moreover, 
in many cases, pragmatic RCTs can deliver comparable 
benefits in terms of direct applicability to routine practice 
settings. Sometimes, emerging fields will be dominated by 
a series of small observational studies. This is ill-advisable, 
because both negative and positive results can be difficult to 
interpret because of issues of confounding and power. This 
exact situation was encountered in a recent systematic review 
of potential benefit of singing for people with Parkinson’s 
disease,31 in which provisional evidence of a benefit on 
speech was found but many questions remained unanswered. 
Nevertheless, one particularly valuable use of observational 
studies of health care interventions that has become more 
common in recent years is the disease registry. Registries can 
provide invaluable insight into cost32 and patient outcomes33 
in the context of routine practice following implementation. 
This offers a different perspective than the pragmatic RCT 
because it evaluates the intervention as it is actually being 
conducted in routine practice rather than a realistic simulation 
of what the intervention might look like in routine practice 
should it be implemented in future. However, as with prag-
matic RCTs, the representativeness of registry populations 
can vary depending on the extent to which ethics boards 
allow an unselected population. For example, in the field of 
rheumatology, among two Aberdeen-based registries, the 
Scotland Registry for Ankylosing Spondylitis34 was allowed 
to conduct an audit of clinical notes of all patients seen 
in secondary care in Scotland with a clinical diagnosis of 
ankylosing spondylitis, while the British Society for Rheu-
matology Biologics Register for Ankylosing Spondylitis35 
was required to seek individual patient consent for all data 
collection. Clearly, the former situation results in a sample, 
at least with regard to data available from routine clinical 
records, which is representative of routine clinical practice, 
while there may be justifiable concerns that the latter situ-
ation may not, if certain types of patient are more likely to 
consent to participate. In a UK context, clinical governance 
and ethics policies have been previously cited as barriers to 
the scientific validity of clinical research.36,37
One particularly long-standing registry that has provided 
invaluable information about the benefits and potential safety 
issues associated with biological therapy in rheumatoid 
arthritis is the British Society for Rheumatology Biologics 
Register in Rheumatoid Arthritis (BSRBR-RA). Having 
reached 15 years38 and still being open to recruitment, 
BSRBR-RA is a good example of what a registry can achieve 
if sufficient financial support can be found to keep it going 
for long term. Such long-term registries, in addition to the 
benefits outlined earlier, offer insight into safety issues that 
are either relatively rare and only emerge in large registries 
or open emerge in the long term, beyond the relatively short 
follow-up period typically afforded by RCTs. As used in 
analyses from BSRBR-RA, propensity score matching 
techniques39 can be used in longitudinal analysis of registry 
data in an effort to overcome confounding by baseline group 
differences, which is ordinarily a substantial disadvantage 
of nonrandomized studies of health care interventions. 
Propensity score matching goes far beyond more traditional 
approaches such as covariate adjustment. This is an example 
of how advances in statistical techniques can help unleash the 
full value of otherwise limited methodologies in order to ben-
efit from their particular strengths. As the confounding issue 
can now be largely addressed, the true benefits of registries in 
terms of observing real-life clinical care can be realized. It is 
important to note that while issues such as confounding and 
missing data can be addressed using statistical techniques, 
bias cannot be corrected for. Therefore, an advantage of 
registries, and pragmatic RCTs, over explanatory RCTs, is 
that they feature far less selection bias relative to everyday 
clinical practice – indeed the only selection bias that may arise 
in a registry study is if ethics board requirements necessitate 
individual patient consent even though the data collection 
occurs in the context of routine health care service provision, 
as discussed earlier. The rise of registries has also spawned 
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another new methodology that combines the strengths of 
registries and those of pragmatic RCTs – this is the registry 
RCT40,41 and it will be interesting to see whether and how 
this method takes off in the next 5–10 years.
Evaluating public health interventions
Health-related interventions can transcend the level of inter-
actions between a patient and a health care provider. Public 
health interventions, unlike interventions in clinical practice, 
operate at the level of treating the population. For example, 
the Faculty of Public Health (UK) defines public health as 
“The science and art of promoting and protecting health and 
well-being, preventing ill-health and prolonging life through 
the organized efforts of society.”42 Public health interventions 
can take a variety of forms from publicity campaigns and 
media coverage to raise awareness of an issue related to a 
health behavior to changes in social policy and legislation. It 
is important, therefore, to define a public health intervention 
broadly, in terms of an intervention that is designed to ben-
efit population health, regardless of whether or not the body 
implementing it is a public health authority. Indeed, there is 
a current trend in many localities,43 including England (but 
hitherto not Scotland), to allocate principal responsibility 
to governmental local authorities rather than health authori-
ties. Nevertheless, these local authorities employ medically 
qualified personnel as Directors of Public Health as well as 
in other consultant-level public health posts.
What many of these myriad approaches have in common 
is that they are not amenable to traditional evaluative methods 
such as the RCT as are often applied to clinical practice set-
tings. This is because it is often either impractical to imple-
ment such a population-level initiative on a test basis or there 
are ethical issues that would prevent randomization, particu-
larly in the context of regulating lifestyle and health behavior. 
For example, it is unethical to randomize humans to smoke 
cigarettes and while it may be ethical to engage individuals 
in a trial of smoking cessation therapy, although some ethical 
issues remain,44 it would be unethical to randomize localities 
in a way that would simulate the effect of the introduction 
of antismoking legislation. There are indeed many areas of 
public health practice and policy in which RCTs are not fea-
sible, including measures to reduce air pollution and smoking 
bans. Therefore, greater extrapolation and interpretation are 
often required when using evidence to inform the real-life 
implementation of such policy interventions.
Observational research is the most appropriate para-
digm to embrace in such settings when ethical or practical 
considerations preclude RCTs. “Natural experiments”45 
can sometimes be used, for example, in comparing health 
outcomes in an area that has adopted a particular policy or 
legislative measure with a similar area that has not done 
so. Often, however, such an opportunity does not arise at 
the right time to evaluate the proposed intervention prior to 
implementation in a given setting, resulting in an after-the-
fact evaluation. This can provide useful information about 
whether or not the intervention achieved its desired goals, 
but, due to the time sequence, cannot be used to inform that 
particular policy decision. A range of approaches must be 
considered, and the best approach will depend on the particu-
lar research question and the social context. One approach 
is to conduct observational assessment of the health effects 
of voluntary health behavior change of the same nature as 
would be encouraged or required by the proposed policy 
intervention. Another approach is to assess the magnitude 
of association between a particular risk factor and a given 
outcome to inform consideration of what the beneficial effect 
of introducing a policy to eliminate (or reduce) this risk 
factor may be. However, natural experiments can also play 
a useful role alongside evidence from other study designs. 
For example, the results of selected local implementation of a 
policy can be compared to other locations without the policy 
change. This can help inform the potential adaptation of the 
policy in other localities. Nevertheless, such an approach is 
not always possible, because it relies on the policy change 
being adopted in a comparable location within a reasonable 
temporal window. There are a range of specific designs that 
can be taken to a natural experiment, and while some require 
a long evaluation period, others such as the regression dis-
continuity design46 do not.
Moreover, while evidence should be an important factor 
in guiding public health practice and policy, there are other 
important considerations to bear in mind. One example is 
the “precautionary principle,” which may lead to measures 
that appear to exceed the current evidence, to provide early 
measures to avoid and mitigate health hazards, even in the 
context of uncertainty.47,48 Moreover, the prevailing political 
climate can play an important role. Perceptions of risk, which 
are central to public health, are culturally bound.49 Moreover, 
political features such as social intervention and the welfare 
state have been shown to have a positive effect on population 
health,50 but are associated with left wing politics,51 that is 
not always popular in the modern world.52
Here, we shall briefly mention a couple of examples of 
how observational research has helped inform public health 
interventions in real-life policy contexts. A study led from 
Aberdeen by Semple et al53 on observed particulate matter 
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exposure in cars depending on whether or not tobacco smok-
ing took place during the journey was cited, alongside other 
observational studies, in a Scottish Government consultation 
document for a Private Members Bill by MSP Jim Hume.54 
In turn, this Bill ultimately led to a prohibition of smoking 
in a motor vehicle carrying a child under the Smoking Pro-
hibition (Children in Motor Vehicles) (Scotland) Act 2016. 
Meanwhile, the evidence base has continued to become 
stronger and now includes a systematic review by Raoof et 
al.55 Meanwhile, following a synergy of a mass petition led 
by Nicola Thorp, research including a systematic review 
of observational studies by Barnish and Barnish56 and the 
coverage of both of these in the mass media, such as an 
influential article by Samuel,57 the UK Government has issued 
a clarification that forcing women to wear footwear that is 
detrimental to their health at work is not in accordance with 
the Equality Act (2010), and discussions are underway as to 
how to address remaining issues of this nature.58
Conclusion
Although the situation may slowly be changing, classical 
RCTs retain a privileged place in the hierarchy of evidence 
for the evaluation of health care and other health-related 
interventions. However, these studies, although highly 
regarded by regulatory authorities, are limited in terms of 
their generalizability and, therefore, direct applicability to 
routine clinical practice. In this review, we have provided 
an overview of a range of ways in which pragmatic and 
observational studies can contribute to our understanding 
of the real-life effectiveness of interventions. We have also 
seen how advances, for example in statistical methodol-
ogy, can help overcome some of the issues previously seen 
to characterize such approaches. For example, pragmatic 
RCTs are useful to assess whether a particular intervention 
is effective in the far-from-ideal conditions that character-
ize routine practice. Registry observational studies offer 
invaluable insight into the real-life effectiveness of an 
intervention following implementation, as opposed to in a 
simulated situation, especially if ethical requirements allow 
for an unselected population. The evaluation of public health 
interventions poses its own unique challenges in terms of 
practicalities and ethics. In some situations, natural experi-
ments are available. However, when they are not, observa-
tional studies can be the only approach available to inform 
the choice of intervention. In conclusion, although classi-
cal RCTs do have a valid place in the evaluation of health 
care interventions, our understanding of how well these 
interventions will work in routine practice would likely be 
enhanced if there was a greater focus on  triangulation to 
integrate evidence from different perspectives. Pragmatic 
and observational studies have an important, if still some-
what underrecognized, role to play in evaluating health 
care interventions, to ensure that they are fit for purpose in 
routine clinical practice settings.
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